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Cells respond to soluble and membrane-bound factors to activate signalling 28 
cascades that control cell proliferation and cell death. Vascular endothelial 29 
growth factor A (VEGF-A) is a soluble ligand that modulates a variety of cellular 30 
responses including cell proliferation and apoptosis. It is not well understood 31 
how VEGF-A signalling pathways regulate cell proliferation and cell death. To 32 
address this, we examined VEGF-A-regulated signalling pathways in the 33 
cytosol and nucleus and functional requirement for such cellular responses. 34 
The VEGF-A-regulated transcription factor, ATF-2, is required for cell cycle 35 
proteins such as p53, p21 and Cyclin D1. A cytosolic serine/threonine protein 36 
kinase (Tpl2) modulates ATF-2-regulated effects on the endothelial cell cycle. 37 
Such regulatory effects impact on endothelial cell proliferation, cell viability and 38 
apoptosis. These cellular effects influence complex cell-based organisation 39 
such as endothelial tubulogenesis. Our study now provides a framework for 40 
incorporating VEGF-A-stimulated signalling events from the cytosol to the 41 
nucleus which helps to understand how cell proliferation and apoptosis are 42 
controlled. 43 
(158 words) 44 
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1. Introduction 48 
 Eukaryote organisms sense changes in the extracellular environment 49 
and modulate signal transduction pathways that control different aspects of cell 50 
physiology and animal function. An important feature of cellular physiology is 51 
to tightly regulate cell proliferation and programmed cell death (apoptosis). One 52 
question is how membrane receptors bind extracellular ligands and trigger 53 
such signalling pathways that modulate cell proliferation and apoptosis [1]. In 54 
higher eukaryotes, a wide variety of membrane receptors exist with ubiquitous 55 
and tissue-specific regulatory functions. One such class of proteins are the 56 
receptor tyrosine kinase (RTK) family which bind extracellular ligands and 57 
transduce signals into the cellular interior, thus modulating cell behaviour and 58 
function [2, 3]. It is well known that the RTK activation modulates cell cycle 59 
progression in a wide variety of cells and tissues. RTKs are thus useful models 60 
to better understand how complex eukaryotes integrate signalling pathways 61 
with cell cycle progression and apoptosis. 62 
 The vascular endothelial growth factor receptor (VEGF) family binds to a 63 
subset of receptor tyrosine kinases (VEGFRs) and have provided valuable 64 
insights into vascular physiology in health and disease states [4, 5]. The 65 
founding member of the VEGF family (i.e. VEGF-A) binds to the pro-angiogenic 66 
receptor, VEGFR2, to regulate many aspects of endothelial function including 67 
cell migration, proliferation and angiogenesis [6]. The role of VEGF-A and 68 
VEGFR2 in promoting signal transduction which impacts on cell migration and 69 
endothelial tubule formation (tubulogenesis) is well-characterised. However, 70 
the effect of VEGF-A on endothelial cell proliferation although clear-cut, is 71 
relatively mild. Interestingly, VEGF-A regulates both cell cycle progression and 72 
metabolic control, indicating an ability to simultaneously modulate different 73 
biochemical pathways [7].  74 
 To answer how VEGF-A regulates biochemical events that contributes to 75 
choices between cell proliferation and apoptosis, we examined the functional 76 
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roles of components of signalling pathways regulated by VEGF-A. Different 77 
studies have identified both cytosolic and nuclear proteins that regulate VEGF-78 
A-stimulated signal transduction, metabolism and gene expression [6, 8]. We 79 
focused on the link between the proto-oncogene and serine/threonine protein 80 
kinase, Tpl2 (MAP3K8), the tumour suppressor and cell cycle regulator, p53, 81 
and the nuclear transcription factor, ATF-2. Our findings in this study link Tpl2-82 
regulated signal transduction impacting on ATF-2 and p53 levels to regulate 83 
cell proliferation and apoptosis which impacts on endothelial tubulogenesis. 84 
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2. Materials and Methods 85 
2.1. Materials 86 
 Antibodies used in this study are goat anti-VEGFR2 (R&D Systems, 87 
Minneapolis, USA), mouse anti-Cyclin D1 (DCS6), mouse anti-p21, rabbit anti-88 
ATF-2, rabbit anti-phospho-ATF-2 (pT71), rabbit anti-cleaved and total 89 
caspase 3, rabbit anti-phospho-VEGFR2-Y1175 (pY1175) (Cell Signaling 90 
Technology, Danvers, USA), mouse anti-p53, mouse anti-Cyclin A2, mouse 91 
anti-Bax, mouse anti-Cyclin B (BD Transduction Laboratories, Oxford, UK), 92 
mouse anti-α-tubulin, mouse anti-actin (Sigma-Aldrich, Poole, UK). Endothelial 93 
cell growth medium (ECGM) and recombinant human VEGF-A165 and VEGF-94 
A121 were from PromoCell (Heidelberg, Germany). 95 
 96 
2.2. Immunoblotting and analysis 97 
 Human umbilical vein endothelial cells (HUVECs) were cultured and 98 
grown as previously described [9]. Cells were seeded into 6-well plates until 99 
~80% confluent, cells were washed twice with PBS and starved overnight in 100 
MCDB131 + 0.2% (w/v) BSA and 2 mM thymidine, to stimulate cell cycle arrest 101 
(G1/S). Starvation media was aspirated and cells stimulated in ECGM + 25 M 102 
2-deoxycytidine, containing (0.25 nM) VEGF-A165 or VEGF-A121 if required. 103 
Cells were then lysed and processed for immunoblot analysis as previously 104 
described [10]. Membranes were imaged using a G:BOX XT4 Chemi imaging 105 
system (Syngene, Cambridge, UK). Band intensity was determined using 2-D 106 
densitometry running on dedicated image analysis software (Syngene).  107 
 108 
2.3. Quantitative real-time PCR analysis 109 
 HUVECs were subjected to control or ATF-specific siRNA duplex 110 
treatments as previously described. Cells were then starved for 2 h in minimal 111 
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media, before stimulation with VEGF-A (25 ng/ml) for 2 h followed by cell lysis 112 
and processing for qRT-PCR analysis. Total cellular RNA was reverse 113 
transcribed into cDNA using random hexamer primers included in the High-114 
Capacity cDNA Archive Kit (Life Technologies) [11]. PCR reactions were 115 
performed in a LightCycler apparatus using the LC-FastStart DNA Master 116 
SYBR Green I kit (Roche Diagnostics, Mannheim, Germany) as described 117 
previously [12]. 2 μg of total RNA were used for first-strand cDNA synthesis 118 
with Superscript II reverse transcriptase and oligo d(T)12–18 primers according 119 
to the manufacturer’s protocol (Life Technologies). Primer sequences used for 120 
qRT-PCR are: human Tpl2 forward primer: 5'- CGC AAG AGG CTG AGT A-3' 121 
and human Tpl2 reverse primer: 5'-TTC CTG TGC ACG AAG AAT CA-3'. All 122 
PCR reactions were optimised at the same annealing temperature of 60°C and 123 
thermocycling for each reaction was subsequently performed in a final volume 124 
of 20 μl containing 2 μl of cDNA sample, 4 mM MgCl2, 0.5 μM of each primer 125 
and 2 μl of LC-FastStart DNA Master SYBR Green I. Samples were initially 126 
denatured for 8 min at 95°C, followed by 45 cycles of denaturation (95°C for 127 
15 sec), annealing (60°C for 5 sec), elongation (72°C for 10 sec), and a short 128 
temperature increase to 82°C for 3 sec (for fluorescence measurements). PCR 129 
products were quantified relative to a housekeeping gene encoding β-actin. 130 
Expression levels of all other genes are given relative to the expression levels 131 
of β-actin by evaluation of their crossing-over points of product accumulation 132 
curves relative to the standard curve of β-actin. All PCR products were checked 133 
by melting point analysis and by agarose gel electrophoresis to verify that 134 
products were of correct length.  135 
 136 
2.4. FUCCI immunofluorescence analysis 137 
  The fluorescent ubiquitinated cell cycle indicator (FUCCI) has been 138 
previously described [13]. Briefly, a novel puromycin-resistant single co-139 
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expression construct was generated as follows. Plasmid pLV-eGFP (Addgene 140 
#36083; a gift from Pantelis Tsoulfas) was digested with BamHI and SalI to 141 
remove the eGFP open reading frame. PCR primers were used to amplify 142 
sequences encoding mKO2-hCdt1 (30/120) (5’-TAG AAG  ACA CCG ACT 143 
CTA GAG GAT CCA TGG TGA GTG TGA TTA AAC-3’ and 5’-ACG TCG CCG 144 
CAG GTC AGC AGG CTG CCT CTG  CCC TCG CCG CTG CCG ATG GTG 145 
TCC TGG TCC TGC GC-3’) and mAG-hGem (1/110) (5’-CAG CCT GCT GAC 146 
CTG CGG CGA CGT GGA GAA CCC CGG CCC CGT GAG CGT GAT CAA 147 
GCC CGA  G-3’ and 5’-ACG TCT CCA CAT GTC AGG CTT CCT CTT CCT 148 
TCT CCG CTT CCC AGC GCC TTT CTC CGT TTT TCT G-3’), and Pac (5’-149 
AAG CCT GAC ATG TGG AGA CGT GGA AGA AAA CCC TGG GCC CGC 150 
CAC CGA GTA CAA GCC CAC G-3’ and 5’-TAA TCC AGA GGT TGA TTG 151 
GCT AGC TCA GGC ACC GGG CTT GCG GGT C-3’), from the FUCCI 152 
plasmid templates [13] and pGIPZ, respectively. Gibson assembly was used to 153 
create pLV-FUCCI, which encodes a T2A peptide linking mKO2-hCdt1 154 
(30/120) with mAG-hGem (1/110), and a P2A peptide linking mAG-hGem 155 
(1/110) with Pac. To overcome difficulties caused by high GC-content in 156 
overlapping regions, the three inserts were joined using splicing by overlap 157 
extension (2) before addition to the assembly reaction. Supernatants 158 
containing lentiviral particles were generated in HEK293T cells using a 3rd 159 
generation packaging system obtained from Addgene. Endothelial cells were 160 
incubated with lentivirus carrying the FUCCI reporter and a puromycin marker 161 
and cultured for up to 3-4 weeks in ECGM containing puromycin (3 g/ml). 162 
 Following transduction with high-titre viral solutions generated in 163 
HEK293T cells, endothelial cells were transfected with specific siRNA duplexes 164 
for 48 h prior to being starved overnight in MCDB131 + 0.2% (w/v) BSA and 2 165 
mM thymidine (G1/S cell cycle arrest). Cells were subsequently trypsinised and 166 
reseeded into 96-well, black-walled plates at 2.5x103 cells per well in ECGM + 167 
25 M 2-deoxycytidine and imaged at 8 h and 30 h post release following 168 
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addition of Hoechst 33342 to visualise nuclear DNA. Image acquisition was 169 
carried out using either a BD Pathway 435 imager or Olympus X81 170 
immunofluorescence microscope equipped with 405 nm, 488 nm, and 543 nm 171 
light-source lines. Image analysis was performed using ImageJ and 172 
Metamorph 6 software (Universal Imaging, Media, PA) on between 400-2000 173 
cells at each time-point per siRNA duplex treatment.  174 
 175 
2.5. Cell viability assays 176 
 3000 HUVECs were seeded per well of a 96-well plate, cultured in 90 l 177 
ECGM for 16-20 h,  before adding 10 l of MTS reagent (CellTiter 96 AQueous 178 
Non-Radioactive Cell Proliferation Assay, Promega, Madison, USA). After 179 
further incubation for 4 h, colour change caused by reduction of the yellow 180 
tetrazolium compound (MTS) by metabolically active cells to brown formazan 181 
was monitored at 490 nm using a Tecan Sunrise plate reader (Mannedorf, 182 
Switzerland). 183 
 184 
2.6. Annexin V apoptosis assay 185 
 20000 HUVECs were seeded into 24-well plates and left overnight for 186 
16-20 h. Media was removed and cells were subjected to RNAi and protein 187 
knockdown as previously described. Cells were gently detached from the 188 
substratum using previously described protocol for processing for flow 189 
cytometry. Before this was carried out, cells were centrifuged at 1000 g for 5 190 
mins and resuspended in 0.5 ml of Annexin V binding buffer using a kit (Sigma-191 
Aldrich, Poole, UK). Annexin V-FITC conjugate (to stain apoptotic cells) and 192 
propidium iodide (to stain DNA of dead or dying cells) was added as 193 
recommended by manufacturer. Samples were then examined using a 194 
Fortessa flow cytometer (Becton Dickinson, UK) and >10000 labelled cells 195 
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were analysed per experiment. Early apoptotic cells show labelling with the 196 
Annexin V-FITC conjugate alone. Live cells show no labelling with either the 197 
propidium iodide or Annexin V-FITC. Necrotic cells are labelled by both 198 
propidium iodide and Annexin V-FITC. 199 
 200 
2.7. Cell proliferation assay 201 
 2000 HUVECs were seeded per well of a 96-well plate and left overnight 202 
for 16-20 h. Media was removed and replaced with serum-free medium for 3 h, 203 
then stimulated with 0.25 nM VEGF-A in 100 µl for 24 h. 10 µM BrdU was 204 
added per well at this point. Cell proliferation ELISA was used according to 205 
manufacturer's protocol (Roche Diagnostics, Mannheim, Germany). Colour 206 
change was developed using 3,3’5,5’-tetramethylbenzidine solution and the 207 
reaction quenched with 1 M H2SO4. Absorbance was measured at 450 nm 208 
using a variable wavelength Tecan Sunrise plate reader (Tecan, Mannedorf, 209 
Switzerland). 210 
 211 
2.8. Tubulogenesis assay  212 
 Primary human foreskin fibroblasts (Promocell) were cultured in 48-well 213 
plates until confluent, before seeding 7500 endothelial cells per well onto the 214 
fibroblast monolayer and left overnight for 20-24 h essentially as previously 215 
described [9]. Briefly, media was aspirated and replaced with fresh media 216 
supplemented with VEGF-A (0.25 nM) every 2-3 days for 7 days. Co-cultures 217 
were fixed in 200 l 10% (v/v) formalin for 20 min at room temperature, 218 
quenched and labelled with mouse anti-human PECAM-1 (CD31) and donkey 219 
anti-mouse Alexa Fluor 594 conjugate as previously described [9]. Processed 220 
samples containing stained endothelial tubules were visualized using an 221 
EVOS-fl inverted digital microscope (ThermoFisher). 3 random fields were 222 
imaged per well. Total tubule length was then quantified from each 223 
-10- 
 
photographic field using the open source software AngioQuant 224 
(www.cs.tut.fi/sgn/csb/angioquant) and values averaged. For a more detailed 225 
methods see elsewhere [9]. 226 
 227 
2.9. Statistics  228 
 We used one-way analysis of variance (ANOVA) followed by Tukey’s 229 
post-hoc test or two-way ANOVA followed by Bonferroni multiple comparison 230 
test using GraphPad Prism software (La Jolla, USA). Significant differences 231 
between control and test groups were evaluated with p values less than 0.05 232 
(*), 0.01 (**), 0.001 (***) and 0.0001 (****) indicated on the graphs or 233 
histograms. Error bars denote mean±SEM.  234 
-11- 
 
3. Results 235 
3.1. ATF-2 modulates p21, p53 and Cyclin D1 levels 236 
 In primary endothelial cells VEGF-A regulates signal transduction and 237 
cell proliferation [14] partially through recruitment of nuclear transcription 238 
factors, including c-fos and other AP-1 components [15]. We have previously 239 
identified a signalling nexus between VEGFR2, the MAP3K family member 240 
Tpl2, and a transcription factor, ATF-2. In previous studies on VEGF-A-241 
stimulated and ATF-2-regulated endothelial gene expression on VCAM-1 [15] 242 
and Tpl2 [16], we find that maximal VEGF-A165-stimulated, ATF-2-regulated 243 
VCAM-1 synthesis occurs 8 h after VEGF-A addition. Under such conditions, 244 
there is complexity in decreased VEGFR2 levels caused by increased 245 
ubiquitination, endocytosis and degradation [15]. However, there is also a rise 246 
in new VEGFR2 synthesis [15], which can also substantially add to VEGFR2 247 
activation in the presence of excess exogenous VEGF-A. However, the 248 
influence of this pathway on endothelial cell cycle progression and survival was 249 
unknown. To ascertain whether different VEGF-A isoforms regulate cytosolic 250 
and nuclear signalling events which impact on the endothelial cell cycle, we 251 
probed the biochemical state of key regulatory proteins associated with such 252 
events (Fig. 1). As previously reported [17], two different VEGF-A isoforms 253 
(VEGF-A165 and VEGF-A121) show differential ability to activate VEGFR2, 254 
revealed by varied phospho-VEGFR2 (Y1175) levels (Fig. 1A). Such signalling 255 
further impacts on gene expression, as shown by increased levels of VCAM-1 256 
in response to VEGF-A165 stimulation for 8 h (Fig. 1A). As ATF-2 is implicated 257 
in the VEGF-A-stimulated (after 8 h) VCAM-1 increase, concomitant with a 258 
decrease in VEGFR2 levels [17], we depleted ATF-2 levels using RNA 259 
interference (RNAi) (Fig. 1A, 1B). Knockdown of ATF-2 levels resulted in ~50% 260 
decrease in this essential nuclear regulator (Fig. 1B). However, ATF-2 261 
knockdown did not affect levels of either Cyclin A2 or Cyclin B, critical drivers 262 
of cell proliferation (Fig. 1A). Unexpectedly, depletion of ATF-2 caused 263 
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elevated levels of two other cell cycle regulators, Cyclin D1 and the cyclin-264 
dependent kinase inhibitor, p21 (Fig. 1A). The latter is a major transcriptional 265 
target of the tumour suppressor p53, suggesting p53 involvement in the 266 
process. 267 
 There is link between VEGF-A-stimulated ATF-2 phosphorylation and 268 
ATF-2 levels [15, 16]. Activation of the p53 tumour suppressor is known to 269 
increase levels of p21, a negative cell cycle regulator, thus potentially 270 
impacting additional cell cycle modifiers including Cyclin D1 [18-20]. We 271 
explored further links between ATF-2 and p53 by knockdown of either protein 272 
alone or together (Fig. 1C). As expected, ATF-2 knockdown abrogated the 273 
VEGF-A-stimulated increase in VCAM-1 expression (Fig. 1C, 1D). ATF-2 274 
knockdown elevated p21 levels substantially. Importantly, p53 levels were also 275 
elevated under such conditions (Fig. 1C, 1E). The >2-fold increase in p53 276 
levels caused by ATF-2 knockdown were reversed by p53 or combined ATF-277 
2/p53 knockdown (Fig. 1E). Under these conditions, ATF-2 knockdown caused 278 
~3.5-fold rise in Cyclin D1 levels (Fig. 1F). Furthermore, the increased p21 and 279 
cyclin D1 expression evident upon ATF-2 depletion were dependent on the 280 
presence of p53, as co-depletion of ATF-2 and p53 abolished the increases 281 
(Fig. 1C-F). However, VCAM1 levels were not rescued by depletion of both 282 
ATF-2 and p53 (Fig. 1D). 283 
 284 
3.2. Tpl2 dependence on ATF-2 and impact on p53 and Cyclin D1 285 
 The MAP3K family member and oncoprotein, Tpl2, which is implicated in 286 
lung carcinogenesis [21] regulates VEGF-A-stimulated angiogenesis [22] and 287 
transduces signals from the cytosol to the nucleus in endothelial cells [16]. To 288 
assess whether Tpl2 is functionally linked to levels of ATF-2 and cell cycle 289 
regulators such as p53, we asked whether RNAi altered protein expression 290 
(Fig. 2A). Knockdown of Tpl2 caused ~60% reduction in protein levels (Fig. 291 
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2B). Tpl2 depletion also supressed ATF-2 expression to levels similar to those 292 
observed after direct ATF-2 knockdown (Fig. 2A). Surprisingly, although ATF-293 
2 knockdown caused >2-fold increase in p53, and Tpl2 depletion also reduced 294 
ATF-2 expression, Tpl2 RNAi had no substantial effect on p53, p21, or Cyclin 295 
D1 protein levels (Fig. 2A, 2D, 2E). However, combined depletion of both ATF-296 
2 and Tpl2 caused p53 and cyclin D1 protein levels, to return to baseline (Fig. 297 
2A, 2D, 2E). Depletion of Tpl2 caused >60% reduction in steady-state Tpl2 298 
levels (Fig. 2B). 299 
 ATF-2 depletion elevates Tpl2 protein expression (Fig. 2A), indicative of 300 
a functional link between the two proteins. To explore this further we carried 301 
out qRT-PCR to analyse the link between ATF-2 and Tpl2 expression (Fig. 2C). 302 
In a comparison between control and VEGF-A-stimulated conditions, we found 303 
~15-fold increase in Tpl2 mRNA levels (Fig. 2C). Depletion of ATF-2 levels 304 
caused reduction in Tpl2 mRNA to background levels (Fig. 2C). ATF-2 305 
knockdown elevates cell cycle regulator levels (cyclin D1, p53, p21) but Tpl2 306 
depletion reverses such effects (Fig. 2D, 2E), suggesting Tpl2 expression is 307 
required for mediating the p53 increase evident upon ATF-2 knockdown. The 308 
presence of ATF-2 might act as a mitotic accelerator or enabler by dampening 309 
the expression of p53 and its downstream cell cycle inhibitors, including p21, 310 
via a mechanism dependent on Tpl2 activity.     311 
 The eukaryote cell cycle is regulated by a combination of protein kinases, 312 
cyclins and transcription factors [20, 23, 24]. The previous data in this study 313 
suggested that ATF-2 levels influences cell cycle proteins. To assess whether 314 
the endothelial cell cycle if affected by ATF-2, we used the fluorescent 315 
ubiquitinated cell cycle indicator (FUCCI) [13] which is a dual reporter system 316 
used to monitor progression through the cell cycle in living cells, tissues and 317 
animals [25]. A lentiviral FUCCI construct was used to transduce primary 318 
endothelial cells and cell synchronisation (see Materials and Methods) before 319 
monitoring of fluorescent reporter proteins, mKO2-hCdt1 (red) for non-cycling 320 
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G1 stage cells, and mAG-hGem (green) for proliferating G2/M stage cells 321 
(green) (Fig. 3A). Under control conditions, stimulation with VEGF-A caused 322 
transient increase in the G1:G2/M ratio after 8 h which is more than 2-fold 323 
higher than that that observed after 30 h (Fig. 3B), indicating a rise in the 324 
number of cells in G2/M phase within soon after VEGF-A stimulation. Here, 325 
depletion of either ATF-2 or p53 had no effect on the G1:G2/M ratio compared 326 
to controls (Fig 3B). However, combined ATF-2/p53 caused a significant >2-327 
fold increase in the proportion of cells in G2/M after 30 h (Fig 3B). Furthermore, 328 
knockdown of Tpl2 caused a dramatic rise in proportion of cells in the G2/M 329 
phase both at the 8 h and 30 h time points (Fig. 3B). However, the relative 330 
difference between the 8 h and 30 h time points was a 2-3-fold change in Tpl2-331 
depleted cells, similar to controls (Fig. 3B). Interestingly, combined ATF-2/Tpl2 332 
knockdown showed little change between the 8 h and 30 h time points (Fig. 333 
3B), suggesting substantial effects on the endothelial cell cycle. 334 
 Cells that are senescent or have exited the cell cycle are in G0, and p53 335 
is a key regulator of cellular senescence [19]. One possibility is that depletion 336 
of cell cycle regulatory factors results in increased endothelial cell senescence 337 
or cell cycle exit. We evaluated the proportion (%) of the endothelial cell 338 
population lacking staining for both mAG and mKO indicative of G0 (Fig. 3C). 339 
This was substantially higher in the cells depleted of ATF-2 (Fig. 3C). However, 340 
this effect was rescued upon combined knockdown of either ATF-2/p53 or ATF-341 
2/Tpl2 (Fig. 3C). Furthermore, we found that in addition to cell cycle arrest, 342 
ATF-2 knockdown also resulted in ~40% decrease in endothelial cell viability 343 
(Fig. 3D). 344 
 345 
3.3. ATF-2, Tpl2 and p53 modulation of apoptosis 346 
 One question arising from these data is how endothelial cells integrate 347 
complex signal transduction pathways with nuclear gene expression to 348 
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influence programmed (i.e. apoptosis) and general (i.e. necrosis) cell death. To 349 
address this, we used flow cytometry (see Materials and Methods) to identify, 350 
necrotic, early and late apoptotic endothelial cell populations (Fig. S1). We 351 
used controls (Fig. S1) to evaluate early and late apoptotic cells compared to 352 
necrotic cells under conditions of specific protein depletion (Fig. S1B). 353 
Quantification of the AnxV-positive population revealed ~4-fold rise in such 354 
endothelial cells upon ATF-2 depletion (Fig. 4A). Tpl2 depletion also caused 355 
>2-fold rise in AnxV-labelled cell population compared to control (Fig. 4A). A 356 
similar profile was observed when the relative cell population was analysed 357 
with early apoptotic cell population marked increased >2-fold upon either ATF-358 
2 or Tpl2 depletion (Fig. 4B). In the analysis of late apoptotic cells, ATF-2 359 
depletion caused a>4-fold rise in apoptotic cells, and only a ~2-fold rise in Tpl2-360 
depleted cells (Fig. 4C). Considering the total apoptotic cell population, the 361 
ATF-2 or Tpl2-depleted cells all show significant 2-3-fold rise in apoptosis (Fig. 362 
4D). In these flow cytometry experiments, simultaneous depletion of ATF-363 
2/Tpl2 or ATF-2/p53 causes a reversal in the effects observed with ATF-2 364 
depletion alone (Fig. 4A-4D).  365 
 To explore the molecular basis for increased endothelial apoptosis 366 
caused by ATF-2 depletion, we assessed the biochemical status of key 367 
apoptotic regulators (Fig. 4E). Immunoblotting of control (scrambled) and ATF-368 
2-depleted endothelial cells revealed an increase in cleaved pro-apoptotic 369 
Caspase 3 (Fig. 4E). There were also increased levels of p53 and pro-apoptotic 370 
Bax proteins in ATF-2-depleted cells (Fig. 4E). Quantification of these data 371 
showed >2-fold rise in cleaved Caspase 3 upon ATF-2 depletion (Fig. 4F).  372 
 373 
3.4. ATF-2, Tpl2 and p53 involvement in VEGF-A-regulated endothelial cell 374 
responses 375 
 VEGF-A promotes multiple endothelial responses including cell viability, 376 
cell proliferation and tubule formation, key features of angiogenesis [4, 5]. We 377 
compared endothelial cell viability upon knockdown of specific cytosolic and 378 
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nuclear factors: ATF-2 knockdown caused ~50% decrease in VEGF-A-379 
stimulated cell viability (Fig. 5A). Tpl2 knockdown also caused ~30% decrease 380 
in VEGF-A-stimulated cell viability (Fig. 5A). However, simultaneous combined 381 
knockdown of either ATF-2/p53, or ATF-2/Tpl2 caused cell viability to return to 382 
baseline levels (Fig. 5A). Depletion of p53 alone had no effect on VEGF-A-383 
stimulated endothelial cell viability (Fig. 5A). 384 
 As VEGF-A is well-known to stimulate cell proliferation, we asked 385 
whether this response was affected by knockdown of components of signal 386 
transduction pathways involving ATF-2 and Tpl2 (Fig. 5B). ATF-2 knockdown 387 
caused ~30% decrease in endothelial cell proliferation; however, knockdown 388 
of p53 or Tpl2 had no effect (Fig. 5B). However, simultaneous knockdown of 389 
ATF-2/p53 or ATF-2/Tpl2 returned cell proliferation to control baseline levels 390 
(Fig. 5B).  391 
 One unique feature of VEGF-A is the capacity to stimulate endothelial 392 
cells to proliferate, migrate and form biological tubes [26]. We used the in vitro 393 
endothelial-fibroblast co-culture assay to evaluate VEGF-A-stimulated 394 
tubulogenesis (Fig. 5C). VEGF-A stimulation causes ~6-fold increase in 395 
average endothelial tubule length under control conditions (Fig. 5D). In 396 
contrast, ATF-2 knockdown caused ~50% decrease in endothelial tubule 397 
length, (Fig. 5D). Although Tpl2 knockdown caused ~4-fold increase in VEGF-398 
A-stimulated tubule length, there was ~35% reduction in tubulogenesis 399 
compared to control (Fig. 5D). Again however, combined knockdown of either 400 
ATF-2/p53 or ATF-2/Tpl2 caused return to baseline levels of VEGF-A-401 
stimulated endothelial tubulogenesis (Fig. 5D). Lack of ATF-2 hampers 402 
endothelial tubule formation through upregulation of p53 expression and 403 
induction of cell cycle arrest, all dependent on the presence of Tpl2.  404 
  405 
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4. Discussion 406 
 One important aspect feature of primary cells and tissues is the balance 407 
between cell survival, proliferation and different types of cell death. Complex 408 
regulatory mechanisms exist to ensure correct timing of cell proliferation in 409 
healthy and diseased states. In this study, we investigated how endothelial 410 
cells balance cytosolic and nuclear signalling which impacts on cell cycle 411 
progression and cell death. Our study suggests a model where Tpl2 receives 412 
signals and modulates the activity of downstream factors which regulate gene 413 
expression and cell cycle progression (Fig. 6). A balance between Tpl2 414 
signalling and ATF-2 nuclear activity is required for normal endothelial 415 
responses (Fig. 6A). Reduction in ATF-2 activity impacts on the endothelial 416 
commitment to cell cycle progression and apoptosis (Fig. 6B). This function 417 
appears dependent on the presence of Tpl2. 418 
 The evidence for this model is based on 4 lines of evidence. Firstly, ATF-419 
2 depletion promotes a rise in p53, p21 and Cyclin D1 levels, but other cyclins 420 
are not affected. This suggests that under such conditions, these endothelial 421 
cells have entered a pro-apoptotic phase coincident with cell cycle arrest. 422 
Secondly, reduction in ATF-2 levels also causes a rise in the proportion of cell 423 
population in senescence (G0), and this coincides with decreased endothelial 424 
cell viability. Thirdly, a reduction in Tpl2 levels cause a corresponding decrease 425 
in ATF-2 levels, although this was not accompanied by elevated p53, p21, or 426 
Cyclin D1 expression, suggesting a functional link between these two proteins, 427 
where Tpl2 may be viewed as a master regulator. Importantly, ATF-2 depletion 428 
blocks the VEGF-A-stimulated rise in Tpl2 levels, suggesting ATF-2 regulates 429 
gene transcription of the Tpl2 locus. Moreover, loss of ATF-2 is reversed by 430 
simultaneous depletion of either Tpl2 or p53, suggesting a regulatory pathway 431 
linking all three proteins (Fig. 6). Finally, such regulatory effects are manifested 432 
in VEGF-A-stimulated endothelial tubulogenesis, which requires coordination 433 
of cell proliferation and migration for biological tube formation. Reduction in 434 
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ATF-2 levels also reduces the efficiency of endothelial tubulogenesis; however, 435 
such effects are reversed by simultaneous depletion of either Tpl2 or p53. This 436 
regulatory pathway (Fig. 6) thus impacts on the VEGF-A-stimulated formation 437 
of biological tubes. 438 
 The tumour progression locus 2 (Tpl2/Cot/MAP3K8) gene product was 439 
originally identified as a serine/threonine protein kinase in T-cells which 440 
regulated signal transduction and cellular responses [27]. Tpl2 is also a proto-441 
oncoprotein, conferring resistance to Raf kinase inhibition [28], promoting 442 
breast cancer [29], keratocanthoma and squamous cell carcinoma [30]. 443 
However, its role in the vascular system is less well-studied, but reports 444 
suggest that it can regulate angiogenesis [22] and diabetic retinopathy [31]. 445 
Our studies now suggest that cytosolic Tpl2 and the nuclear transcription factor 446 
ATF-2, are part of a pathway that controls cell cycle progression and apoptosis. 447 
The communication between Tpl2 and ATF-2 may occur directly: 448 
hyperphosphorylation of ATF-2 is implicated with increased signalling through 449 
the MAPK pathway [15]. Recent studies suggest that pharmacological 450 
inhibition of p38 MAPK, JNK and AKT signal transduction pathways had little 451 
or no effect on ATF-2 phosphorylation in endothelial cells [15]. One possibility 452 
is that signalling through the canonical MAPK pathway leads to Tpl2 453 
phosphorylation, activation and translocation into the nucleus in a manner 454 
analogous to ERK1/2. It has been reported that Tpl2 activity is required for 455 
phosphorylation of nuclear factors including ATF-2 [16, 32], implying a 456 
functional role in nuclear gene expression. Importantly, a direct nuclear role of 457 
Tpl2 has also been reported [30]. This raises the possibility of Tpl2 itself 458 
responding to VEGFR2 activation, phosphorylation via canonical (MAPK) or 459 
non-canonical pathways which enables nuclear translocation, transcription p 460 
factor phosphorylation and modulation of nuclear gene transcription. In 461 
endothelial cells, VEGF-A-stimulated signal transduction through a non-462 
canonical signal transduction pathway involving the MEK5-ERK5 axis impacts 463 
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on a range of vascular responses [33], which could have relevance to Tpl2 464 
regulation in this context. In tumour cells, there is evidence that Tpl2 activity is 465 
linked to ERK5 status [34]. 466 
 There is a notable relationship between Tpl2 and ATF-2 levels. 467 
Decreased Tpl2 levels also cause a substantive decrease in ATF-2 levels; 468 
combined ATF-2/Tpl2 knockdown reverses effects caused by ATF-2 depletion 469 
alone. However, decreased ATF-2 levels alone, increase Tpl2, p53, cyclin D1 470 
and p21 levels; this is not evident when Tpl2 is depleted in isolation, despite 471 
ATF-2 levels also falling. Tpl2 expression or activity, appears necessary to 472 
allow ATF-2 depletion to stabilise or activate p53, and promote cell cycle arrest. 473 
One explanation is that decreased ATF-2 phosphorylation, due to loss of 474 
upstream Tpl2, increases post-translational modifications on ATF-2 leading to 475 
increased proteolysis and clearance. The loss of ATF-2 leading to increased 476 
Tpl2 (Fig. 6B) could be explained by a possible role for ATF-2 in repressing 477 
TPL2 nuclear gene expression. Alternatively, ATF-2 could activate 478 
transcription of genes encoding ubiquitin ligases; such enzymes could target 479 
components of the Tpl2-regulated pathway. Protein phosphorylation and 480 
ubiquitination are strongly linked in many signal transduction pathways to 481 
control signalling and protein levels. As p53 undergoes complex post-482 
translational modifications including phosphorylation and ubiquitination [35], 483 
one explanation is that decreased ubiquitination due to reduced ATF-2 activity 484 
could drive increased p53 levels. Indeed, Tpl2 has been shown to regulate the 485 
activity of the main p53 E3 ubiquitin ligase, HDM2 [30]. ATF-2 loss may activate 486 
Tpl2 to reduce HDM2 activation or expression, allowing p53 to escape 487 
proteasomal degradation and undergo nuclear accumulation. Furthermore, 488 
both p21 and Cyclin D1 are also regulated by ubiquitination and proteolysis, 489 
suggesting that ATF-2-regulated gene expression could have impact in this 490 
context.  491 
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 In conclusion, our study shows that in primary endothelial cells, basal and 492 
ligand-activated signalling pathways are tightly regulated to ensure that signals 493 
from the cytosol impact on nuclear gene expression and nuclear protein 494 
function. A major finding is that a signalling axis involving Tpl2 serine/threonine 495 
protein kinase and ATF-2 transcription factor with a wider impact on key cell 496 
cycle regulators such as p53, p21 and Cyclin D1. This work also raises new 497 
questions on the mechanisms of gene expression and the nature of post-498 
translational modifications that govern the levels of key cell cycle regulators.  499 
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FIGURE LEGENDS  583 
Figure 1. VEGF-A-regulated gene expression exhibits dependence on 584 
ATF-2 and p53.  (A) Endothelial cells subjected to treatment with siRNA 585 
duplexes (scrambled or ATF-2) were treated under serum-free (SF), normal 586 
growth media or VEGF-A165 or VEGF-A121 isoforms for 8 h followed by lysis and 587 
immunoblotting (see Materials and Methods). Blots were probed using 588 
antibodies specific for phospho-VEGFR2 (pY1175), VEGFR2, VCAM-1, ATF-589 
2, p21, actin, cyclins A2, B or D1. (B) Quantification of relative ATF-2 levels 590 
after treatment with control (scrambled siRNA) or ATF-2 siRNA duplexes. (C) 591 
Endothelial cells subjected to treatment with control untreated, scrambled, 592 
ATF-2 and ATF-2/p53 combined siRNA duplexes were non-stimulated (-) or 593 
treated with VEGF-A165 or VEGF-A121 isoforms (+) followed by lysis, and 594 
immunoblotting with antibodies specific for phospho-VEGFR2, VEGFR2, 595 
VCAM-1, p53, p21, phospho-ATF-2, ATF-2, cyclin D1 or tubulin. (D) 596 
Quantification of relative levels of VCAM-1 levels in control, scrambled, ATF-2, 597 
p53 and combined ATF-2/53 siRNA treatments under normal starvation 598 
(control) or VEGF-A165 isoform (165) stimulation. (E) Quantification of relative 599 
p53 levels in control, scrambled, ATF-2, p53 and combined ATF-2/53 siRNA 600 
treatments. (F) Quantification of relative levels of cyclin D1 levels after 601 
treatment with control, scrambled, ATF-2, p53 and combined ATF-2/53 siRNA 602 
duplexes. Error bars indicate ±SEM (n≥3); significance is indicated by the 603 
asterisks shown when p<0.05 (*), p<0.01 (**), p<0.001 (***), p<0.0001 (****). 604 
 605 
Figure 2. ATF-2 and Tpl2 regulate p53 and cyclin D1 levels in endothelial 606 
cells. (A) Endothelial cells subjected to treatment with control untreated, 607 
scrambled, ATF-2 or combined ATF-2/p53 siRNA duplexes were lysed and 608 
immunoblotted with antibodies specific for VEGFR2, p53, p21, Tpl2, phospho-609 
ATF-2, ATF-2, cyclin D1 and tubulin. (B, D, E) Quantification of relative protein 610 
levels of (B) Tpl2, (D) p53, and (E) cyclin D1 after treatment with different 611 
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siRNA duplexes. (C) Quantification of relative Tpl2 RNA levels after treatment 612 
with control or ATF-2-specific siRNA duplexes. HUVECs treated with either 613 
control scrambled siRNA or ATF-2-specific siRNA duplexes, serum starved for 614 
2 h, stimulated with VEGF-A before lysis and qRT-PCR analysis (see Materials 615 
and Methods). Tpl2 RNA levels were normalised relative to control siRNA 616 
treatment. (B-E) Error bars indicate ±SEM (n≥3); significance is indicated by 617 
the asterisks shown when p<0.05 (*), p<0.01 (**), p<0.001 (***), p<0.0001 618 
(****). 619 
 620 
Figure 3. The endothelial cell cycle shows regulation by ATF-2, Tpl2 and 621 
p53. (A) Endothelial cells stably expressing the FUCCI reporter (see Materials 622 
and Methods) were subjected to treatment with scrambled, ATF-2, p53 and 623 
Tpl2 siRNA duplexes followed by synchronization and stimulation with 0.25 nM 624 
VEGF-A165 (VEGF-A) for 8 h or 30 h before fixation and visualization using 625 
fluorescence microscopy. Quantification of endothelial cell populations after 626 
treatment with scrambled, ATF-2, p53 and Tpl2, ATF-2/p53, ATF-2/Tpl2 siRNA 627 
duplexes as shown in (B) G1/M, and (C) G0. (D) Quantification of endothelial 628 
viability in cells subjected to treatment with control, scrambled or ATF-2 siRNA 629 
duplexes. Error bars indicate ±SEM (n≥3); significance is indicated by the 630 
asterisks shown when p<0.05 (*), p<0.01 (**), p<0.001 (***). 631 
 632 
Figure 4. ATF-2 levels influence endothelial cell apoptosis. (A-D) 633 
Endothelial cells were subjected to untreated control, scrambled, ATF-2, p53, 634 
Tpl2, ATF-2/p53, ATF-2/Tpl2 siRNA duplexes before flow cytometry analysis 635 
using combined propidium iodide and Annexin V-FITC staining (see Materials 636 
and Methods). Quantification of (A) AnnexinV-labelled cell population, (B) early 637 
apoptotic cells, (C) late apoptotic cells, and (D) total apoptotic cells after 638 
treatment with different siRNA duplexes followed by flow cytometry. Error bars 639 
indicate ±SEM (n≥3); significance is indicated by the asterisks shown when 640 
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p<0.05 (*), p<0.001 (***). (E) Endothelial cells subjected to treatment with 641 
scrambled or ATF-2-specific siRNA duplexes were lysed and immunoblotted 642 
with antibodies specific for ATF-2, cleaved caspase 3, caspase 3, p53, Bax 643 
and tubulin. (F) Quantification of relative levels of cleaved Caspase 3 in 644 
endothelial cells subjected to treatment with scrambled or ATF-2-specific 645 
siRNA duplexes. Error bars indicate ±SEM (n≥3); significance is indicated by 646 
the asterisks, p<0.01 (**). 647 
 648 
Figure 5. ATF-2, Tpl2 and p53 levels modulate endothelial cell viability, 649 
proliferation and tubulogenesis. Quantification of endothelial cell (A) 650 
viability, (B) proliferation, and (C) tubulogenesis after treatment with different 651 
siRNA duplexes as indicated in each panel. In panel C, endothelial cells were 652 
treated with different siRNA duplexes before assaying for tubulogenesis (see 653 
Materials and Methods) by growth in normal medium (control) or VEGF-A165 654 
stimulated (165) tubulogenesis. In panels A-C, error bars indicate ±SEM (n≥3); 655 
significance is indicated by the asterisks shown when p<0.05 (*), p<0.01 (**), 656 
p<0.001 (***), p<0.0001 (****). (D) Endothelial cells were treated with different 657 
siRNA duplexes (scrambled, ATF-2, p53, Tpl2, ATF-2/p53, ATF-2/Tpl2) before 658 
assaying for tubulogenesis. PECAM-1 staining was used for detecting 659 
endothelial tubules using fluorescence microscopy (see Materials and 660 
Methods). Bar, 1000 m. 661 
 662 
Figure 6. Regulation of endothelial cell cycle progression and apoptosis 663 
by ATF-2, p53 and Tpl2. (A) Under normal or steady-state conditions, the Tpl2 664 
protein kinase maintains ATF-2 phosphorylation (Step 1) which negatively 665 
regulates p53 levels, impacting on p21 and cyclin D1 expression (Step 2). ATF-666 
2 also negatively regulates Tpl2 levels. This translates into normal endothelial 667 
cell cycle progression and function (Step 3). (B) Under conditions of reduced 668 
ATF-2 activity or levels there is a rise in Tpl2 levels (Step 4) which positively 669 
-26- 
 
regulates p53 levels, impacting on p21 and cyclin D1 expression (Step 5). This 670 
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Figure S1. Flow cytometry analysis of endothelial cell apoptosis. (A) Control untreated
endothelial cells were subjected to no labelling or with either propidium iodide (PI) or AnnexinV-
FITV (AV-FITC). (B) Endothelial cells subjected to treatments using scrambled, ATF-2, p53, Tpl2,
ATF-2/p53, ATF-2/Tpl2 siRNA duplexes before flow cytometry analysis using combined propidium
iodide and Annexin V-FITC staining (see Materials and Methods). The different cell populations
(healthy, necrotic, early apoptotic and late apoptotic) are indicated in each quadrant.
